Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $601.35 | 9 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GE HEALTHCARE | $161.16 | 2 | $0 (2019) |
| Blue Earth Diagnostics Limited | $140.14 | 2 | $0 (2019) |
| GENZYME CORPORATION | $110.62 | 1 | $0 (2022) |
| Lilly USA, LLC | $95.16 | 1 | $0 (2017) |
| Astellas Pharma US Inc | $51.48 | 1 | $0 (2019) |
| Lantheus Medical Imaging, Inc. | $26.86 | 1 | $0 (2018) |
| Siemens Medical Solutions USA, Inc. | $15.93 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $110.62 | 1 | GENZYME CORPORATION ($110.62) |
| 2019 | $227.24 | 3 | Blue Earth Diagnostics Limited ($97.58) |
| 2018 | $168.33 | 4 | GE HEALTHCARE ($82.98) |
| 2017 | $95.16 | 1 | Lilly USA, LLC ($95.16) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/12/2022 | GENZYME CORPORATION | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $110.62 | General |
| Category: Oncology | ||||||
| 11/08/2019 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $51.48 | General |
| 07/22/2019 | Blue Earth Diagnostics Limited | Axumin (Drug) | Food and Beverage | In-kind items and services | $97.58 | General |
| Category: Diagnostic Imaging | ||||||
| 01/04/2019 | GE HEALTHCARE | — | Food and Beverage | Cash or cash equivalent | $78.18 | General |
| 12/13/2018 | GE HEALTHCARE | — | Food and Beverage | Cash or cash equivalent | $82.98 | General |
| 10/27/2018 | Lantheus Medical Imaging, Inc. | Technelite (Drug) | Food and Beverage | In-kind items and services | $26.86 | General |
| Category: Radiopharmaceutical | ||||||
| 06/24/2018 | Blue Earth Diagnostics Limited | Axumin (Drug) | Food and Beverage | In-kind items and services | $42.56 | General |
| Category: Diagnostic Imaging | ||||||
| 03/12/2018 | Siemens Medical Solutions USA, Inc. | Axumin (Device) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: MI - Nuclear Medicine (incl. PETNET & MIBR) | ||||||
| 08/23/2017 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $95.16 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 1,110 | 1,921 | $4.6M | $1.4M |
| 2022 | 5 | 1,034 | 1,536 | $4.4M | $1.3M |
| 2021 | 4 | 616 | 700 | $2.0M | $564,955 |
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 479 | 603 | $3.4M | $865,462 | 25.6% |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | Office | 2023 | 71 | 611 | $348,645 | $249,377 | 71.5% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 77 | 88 | $591,800 | $126,317 | 21.3% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 469 | 596 | $178,800 | $69,627 | 38.9% |
| A9592 | Copper cu-64, dotatate, diagnostic, 1 millicurie | Office | 2023 | 14 | 23 | $88,700 | $69,306 | 78.1% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 457 | 602 | $3.4M | $874,427 | 25.9% |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | Office | 2022 | 49 | 234 | $235,658 | $174,293 | 74.0% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2022 | 63 | 75 | $504,375 | $109,216 | 21.7% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 452 | 608 | $182,400 | $71,549 | 39.2% |
| A9592 | Copper cu-64, dotatate, diagnostic, 1 millicurie | Office | 2022 | 13 | 17 | $64,100 | $50,582 | 78.9% |
| 78815 | Nuclear medicine study with ct imaging skull base to mid-thigh | Office | 2021 | 282 | 301 | $1.7M | $435,803 | 25.8% |
| A9588 | Fluciclovine f-18, diagnostic, 1 millicurie | Office | 2021 | 14 | 59 | $69,216 | $53,997 | 78.0% |
| 78816 | Nuclear medicine study with ct imaging whole body | Office | 2021 | 25 | 26 | $174,850 | $37,725 | 21.6% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2021 | 295 | 314 | $94,200 | $37,429 | 39.7% |
About Dr. Borys Krynyckyi, MD
Dr. Borys Krynyckyi, MD is a Nuclear Medicine healthcare provider based in Galloway, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1003892613.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Borys Krynyckyi, MD has received a total of $601.35 in payments from pharmaceutical and medical device companies, with $110.62 received in 2022. These payments were reported across 9 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($601.35).
As a Medicare-enrolled provider, Krynyckyi has provided services to 2,760 Medicare beneficiaries, totaling 4,157 services with total Medicare billing of $3.2M. Data is available for 3 years (2021–2023), covering 14 distinct procedure/service records.
Practice Information
- Specialty Nuclear Medicine
- Other Specialties Nuclear Medicine
- Location Galloway, NJ
- Active Since 12/16/2005
- Last Updated 05/06/2025
- Taxonomy Code 207U00000X
- Entity Type Individual
- NPI Number 1003892613
Products in Payments
- Axumin (Drug) $140.14
- LIBTAYO (Biological) $110.62
- AMYVID (Drug) $95.16
- Technelite (Drug) $26.86
- Axumin (Device) $15.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.